Investors

Creating an African Centre of Excellence

Ownership

The Biovac Institute is a public private partnership (PPP) between the Department of Health and its strategic equity partner, the Biovac Consortium, which incorporated the State Vaccine Institute into a commercial company in 2003. The Biovac Consortium is comprised of Biovac Holdings, Bionet, the Disability Employment Concerns Trust (an empowerment investment trust) and Litha Healthcare Holdings.

Vision

To be a Centre of Excellence rooted in Africa for the development and manufacture of affordable, high-quality vaccines to meet Africa and the developing world’s needs.

Mission

• To ensure that South Africa has the required domestic capacity to respond to local and regional needs for the provision of basic EPI vaccines
• To provide in the long-term for the research, development and the introduction of novel vaccines, focusing on the development of vaccines relevant to South Africa and Africa’s particular needs.

Strategic Objectives

• Ensure economic viability
  • To become an economically viable vaccines producer applying the principles of cGMP
  • No financial or other subsidies necessary
  • Capital raised during the normal course of business
  
  
• Develop and retain local vaccine production skills
  • To develop and retain vaccine-related skills and ensure the continued development of the biotechnology sector
  • Implement a comprehensive skills development programme
  • Build a pipeline of talented vaccines professionals
  
  
• Enable BBBEE
  • To enable the genuine economic empowerment of Previously Disadvantaged Groups
  • To implement a comprehensive transformation strategy
  • To obtain a BBBEE rating of 4 by 2011
  
  
• Establish a strong R&D capability
  • To establish a strong R&D capability, focusing on the development of vaccines relevant to South Africa and developing world
  • Staff turnover of less than 5% by 2012
  • Established R&D platforms, including pre-clinical and clinical, by Q3 2012
  
  
• Establish domestic capacity
  • To establish domestic capacity in vaccine production
  • Complete establishment of the full vaccines value chain infrastructure
  • Ensure full regulatory compliance
  • Achieve economic production volumes
  
  
• Create a competitive platform for export
  • To ensure that any development in this sector in South Africa opens access to export markets as potential customers
  • Double export revenue to R 72 million (2009) by 2013
  • To find and introduce appropriate products for sub-Saharan African markets
  • To implement a full service offering
  • To develop and introduce a range of TBI’s own products.

>> Discover what is in The Biovac Institute Research Pipeline
>> Find out more about the organisation’s expanding Manufacturing
>> Find out more About Us
>> The Biovac Institute Executive TeamProducts